Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 1, 2011, Pages 4-15

  Dhandapany, Perundurai S ^a   Fabris, Frank ^a   Tonk, Rahul ^b   Illaste, Ardo ^a   Karakikes, Ioannis ^a   Sorourian, Mehran ^a   Sheng, Jipo ^a   Hajjar, Roger J ^a   Tartaglia, Marco ^c   Sobie, Eric A ^a   Lebeche, Djamel ^a   Gelb, Bruce D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Calcineurin; Cardiomyocyte hypertrophy; ERK1 2; Hypertrophic cardiomyopathy; MEK1 2; Noonan LEOPARD syndrome; RAF1

Indexed keywords

ASPARAGINE; ASPARTIC ACID; CALCINEURIN; CALCIUM; CYCLOSPORIN A; ISOLEUCINE; LEUCINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MUTANT PROTEIN; RAF PROTEIN; RAF1 PROTEIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; SERINE; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; VALINE;

ANIMAL CELL; ARTICLE; CALCIUM SIGNALING; CELL TYPE; CONTROLLED STUDY; ENZYME INHIBITION; HEART MUSCLE CELL; HYPERTROPHIC CARDIOMYOPATHY; LEOPARD SYNDROME; NONHUMAN; NOONAN SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; WILD TYPE;

ADENOVIRIDAE; ANIMALS; ANIMALS, NEWBORN; CALCINEURIN; CALCIUM SIGNALING; CARDIOMEGALY; CARDIOMYOPATHY, HYPERTROPHIC; CYCLOSPORINE; DISEASE MODELS, ANIMAL; LEOPARD SYNDROME; MUTATION; MYOCYTES, CARDIAC; NOONAN SYNDROME; PROTO-ONCOGENE PROTEINS C-RAF; RAS PROTEINS; RATS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

RATTUS;

EID: 79956311824     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.03.001     Document Type: Article

References (36)

1. Heineke J., Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006, 7(8):589-600.
2. Molkentin J.D. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res 2004, 63(3):467-475.
3. Pandit B., Sarkozy A., Pennacchio L.A., Carta C., Oishi K., Martinelli S., et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 2007, 39(8):1007-1012.
4. Razzaque M.A., Nishizawa T., Komoike Y., Yagi H., Furutani M., Amo R., et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 2007, 39(8):1013-1017.
5. Kim M., Oh J.K., Sakata S., Liang I., Park W., Hajjar R.J., Lebeche D. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol 2008, 45(2):270-280.
6. Noble C., Mercer K., Hussain J., Carragher L., Giblett S., Hayward R., et al. CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Mol Cell 2008, 31(6):862-872.
7. Nicol R.L., Frey N., Pearson G., Cobb M., Richardson J., Olson E.N. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J 2001, 20(11):2757-2767.
8. Liu Q., Sargent M.A., York A.J., Molkentin J.D. ASK1 regulates cardiomyocyte death but not hypertrophy in transgenic mice. Circ Res 2009, 105(11):1110-1117.
9. Liu Q., Wilkins B.J., Lee Y.J., Ichijo H., Molkentin J.D. Direct interaction and reciprocal regulation between ASK1 and calcineurin-NFAT control cardiomyocyte death and growth. Mol Cell Biol 2006, 26(10):3785-3797.
10. Chen J., Fujii K., Zhang L., Roberts T., Fu H. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci USA 2001, 98(14):7783-7788.
11. Sanna B., Bueno O.F., Dai Y.S., Wilkins B.J., Molkentin J.D. Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth. Mol Cell Biol 2005, 25(3):865-878.
12. Braz J.C., Bueno O.F., Liang Q., Wilkins B.J., Dai Y.S., Parsons S., et al. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest 2003, 111(10):1475-1486.
13. Wu H., Rothermel B., Kanatous S., Rosenberg P., Naya F.J., Shelton J.M., et al. Activation of MEF2 by muscle activity is mediated through a calcineurin-dependent pathway. EMBO J 2001, 20(22):6414-6423.
14. Colella M., Pozzan T. Cardiac cell hypertrophy in vitro: role of calcineurin/NFAT as Ca2+ signal integrators. Ann NY Acad Sci 2008, 1123:64-68.
15. Colella M., Grisan F., Robert V., Turner J.D., Thomas A.P., Pozzan T. Ca2+ oscillation frequency decoding in cardiac cell hypertrophy: role of calcineurin/NFAT as Ca2+ signal integrators. Proc Natl Acad Sci USA 2008, 105(8):2859-2864.
16. Hoshijima M., Sah V.P., Wang Y., Chien K.R., Brown J.H. The low molecular weight GTPase Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes. Involvement of Rho kinase. J Biol Chem 1998, 273(13):7725-7730.
17. Hunter J.J., Tanaka N., Rockman H.A., Ross J., Chien K.R. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 1995, 270(39):23173-23178.
18. Bueno O.F., De Windt L.J., Tymitz K.M., Witt S.A., Kimball T.R., Klevitsky R., et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 2000, 19(23):6341-6350.
19. Wang L., Proud C.G. Ras/Erk signaling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes. Circ Res 2002, 91(9):821-829.
20. Sanada S., Node K., Minamino T., Takashima S., Ogai A., Asanuma H., et al. Long-acting Ca2+ blockers prevent myocardial remodeling induced by chronic NO inhibition in rats. Hypertension 2003, 41(4):963-967.
21. Harris I.S., Zhang S., Treskov I., Kovacs A., Weinheimer C., Muslin A.J. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 2004, 110(6):718-723.
22. Purcell N.H., Wilkins B.J., York A., Saba-El-Leil M.K., Meloche S., Robbins J., Molkentin J.D. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci USA 2007, 104(35):14074-14079.
23. Kehat I., Davis J., Tiburcy M., Accornero F., Saba-El-Leil M.K., Maillet M., et al. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ Res 2011, 108(2):176-183.
24. Ichida M., Finkel T. Ras regulates NFAT3 activity in cardiac myocytes. J Biol Chem 2001, 276(5):3524-3530.
25. Chen P.C., Wakimoto H., Conner D., Araki T., Yuan T., Roberts A., et al. Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome-associated Sos1 mutation. J Clin Invest 2010, 120(12):4353-4365.
26. Molkentin J.D., Lu J.R., Antos C.L., Markham B., Richardson J., Robbins J., Grant S.R., Olson E.N. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93(2):215-228.
27. Molkentin J.D., Robbins J. With great power comes great responsibility: using mouse genetics to study cardiac hypertrophy and failure. J Mol Cell Cardiol. 2009, 46(2):130-136.
28. Nava C., Hanna N., Michot C., Pereira S., Pouvreau N., Niihori T., et al. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome. J Med Genet 2007, 44(12):763-771.
29. Armour C.M., Allanson J.E. Further delineation of cardio-facio-cutaneous syndrome: clinical features of 38 individuals with proven mutations. J Med Genet 2008, 45(4):249-254.
30. Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A., Cruz M.S., et al. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 2006, 311(5765):1287-1290.
31. Dentici M.L., Sarkozy A., Pantaleoni F., Carta C., Lepri F., Ferese R., et al. Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations. Eur J Hum Genet 2009, 17(6):733-740.
32. Rodriguez-Viciana P., Rauen K.A. Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome. Meth Enzymol 2008, 438:277-289.
33. Ko J.M., Kim J.M., Kim G.H., Yoo H.W. PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome. J Hum Genet 2008, 53(11-12):999-1006.
34. Kobayashi T., Aoki Y., Niihori T., Cavé H., Verloes A., Okamoto N., et al. Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation. Hum Mutat 2010 Mar, 31(3):284-294.
35. Gripp K.W., Lin A.E., Stabley D.L., Nicholson L., Scott C.I., Doyle D., et al. HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet A 2006, 140(1):1-7.
36. Zheng M., Dilly K., Dos Santos Cruz J., Li M., Gu Y., Ursitti J.A., et al. Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart. Am J Physiol Heart Circ Physiol 2004, 286(1):H424-H433.